Company Profile

Candel Therapeutics (AKA: Advantagene Inc)
Profile last edited on: 12/2/2023      CAGE: 47B55      UEI: MPKRJM6FJFL8

Business Identifier: Immunotherapy as an adjuvant to standard cancer therapies
Year Founded
1999
First Award
2003
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

117 Kendrick Sreet Suite 450
Needham, MA 02494
   (617) 916-5445
   info@candeltx.com
   www.candeltx.com
Location: Single
Congr. District: 04
County: Norfolk

Public Profile

Developing oncolytic viral immunotherapies that empower the immune system to fight cancer, Candel Therapeutics - formerly dba as Advantagene, Inc. - is a (now) publicly traded (NASDAQ:CADL (July 2021) biopharmaceutical company structured around saving, extending and improving the lives of cancer patients and their families through use of innovative and personalized cancer immunotherapies. The firm's lead effort is the proprietary Gene Mediated Cytotoxic Immunotherapy™ (GMCI™) - a platform technology designed to stimulate a patient’s immune system naturally to fight against the cancer. Based on a relatively low cost and readily available “off-the-shelf” viral vector product (aglatimagene besadenovec; a.k.a. AdV-tk) that generates a powerful patient-specific anti-tumor immune response in-vivo, GMCI™is a novel and versatile technology that can be applied to a variety of solid tumors. Used for many years by hundreds of patients,, GMCI™has an established safety profile lacking the numerous side effects typically associated with cancer therapies. Synergistic with standard of care radiation, surgery, and some chemotherapy GMCI has a unique mechanism of action: focused on the immune system toward a patient’s own unique cancer, GMCI’s safety and benign side effect profile can improve patient outcomes without interrupting therapies currently trusted by physicians and patients. Achieved results of Advantagene's early studies, working with the support of esteemed and influential leaders in the oncology community, are promising showing several unique characteristics providing benefits to patients, payors and providers that few other, if any, cancer therapies can deliver. Advantagene has understaken GMCI™ clinical cancer studies in prostate, brain, lung and pancreas, with notable clinical results to date. Further, the firm is researching potential use of GMCI in other solid tumor indications.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
75-99
Revenue Range
7.5M-10M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : CADL
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Estuardo Aguilar-Cordova -- Founder & CEO

  Paul Peter Tak -- President & Chief Executive Officer

  Laura K Aguilar -- CMO

  Francesca Barone -- Chief Scientific Officer

  Madhu Chhikara

  Daniel Giroux -- Vice President, Manufacturing

  Brian Guzik -- Director, Business Development

  Douglas Jolly

  Glenn Mattes -- COO and Director

  Fiona Patterson -- Director, Clinical Operations

  Stephen Rocamboli -- Chief Business Officer